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INTRODUCTION 
Haemophagocytic syndrome (HPS) also known as the Haemophagocytic 
lymphohistocytosis (HLH) is an aggressive and potentially fatal syndrome that 
results from inappropriate prolonged activation of lymphocytes and 
macrophages. The first reported case of HLH was described in 1952 by 
Farquhar and Claireaux
(1) 
 who called the disease as “Familial Hemophagocytic 
Reticulosis”. It is traditionally divided into Primary\ Familial and Acquired\ 
Secondary. The Familial HLH is due to gene mutations most commonly 
involving the perforin gene while secondary HLH can occur in a wide variety 
of conditions including infections, autoimmune disorders to malignancies. The 
pathological hallmark of the syndrome is aggressive proliferation of 
macrophages/histiocytes in the reticuloendothelial system that are seen 
phagocytosing the haematopoietic elements.
(2)
 
The incidence is more common in the paediatric population, the highest 
between birth to 18 months of age. The estimated incidence of HLH is 1.2 
cases per million individuals per year. However this is most likely an under 
estimate because most of the cases results in death before they are diagnosed , 
some remain undiagnosed while some are not reported. 
The pathogenetic hallmark for HLH is defective NK cell function. NK 
cell is a cell of innate immunity which plays an important role in removing 
stress induced and virus infected cells. In HLH there is a defective NK cell 
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function which can be familial or acquired. Defective NK cell leads to 
persistent activation of macrophages and T helper cell which results in 
hypercytokinemia. This hypercytokinemia leads to the various manifestations 
of HLH.  
Patients with HPS are commonly very ill at the time of presentation. 
They usually present with high persistent fever, anaemia, splenomegaly and 
CNS manifestations. The HLH society-2004 has laid down guidelines for the 
diagnostic criteria for HLH. Minimal diagnostic parameters are fever, 
cytopenia, splenomegaly, abnormal liver function tests, elevated serum 
triglycerides and serum ferritin, low serum fibrinogen and haemophagocytosis 
in  bone marrow aspiration. Two highly sensitive diagnostic markers are 
increased plasma concentration of the alpha chain of soluble IL2 receptor 
(CD25) and impaired NK cell activity. The HLH society in 1994 has laid down 
therapeutic guidelines for the treatment of HLH. An improved revised 
therapeutic criteria came in 2004. This 2004 guideline mainly involves three 
treatment regimens - initial, continuation and reactivation therapy. However 
though disease control can be established with these treatment regimens, a 
complete cure can be established mainly by haematopoitic stem cell 
transplantation. After the advent of improved conditioning and graft versus 
host disease regimen the success of HSCT in patients with HLH has 
dramatically improved. 
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The Department of Pathology, PSGIMS & R receives bone marrows of 
patients with a spectrum of various neoplastic and non-neoplastic disorders. In 
this study we propose to evaluate the spectrum of presentations of 
haemophagocytic syndrome by identifying haemophagocytic activity in the 
bone marrows received and correlating with clinical and biochemical 
parameters that are included in the Haemophagocytic lymphohistocytosis 
(HLH) diagnostic criteria. Since the overall prognosis depends on early 
diagnosis and prompt treatment, we in this study propose to elucidate the 
aetiopathogenesis of this diverse disorder which may play a significant role in 
the prognosis of the patient. 
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AIM AND OBJECTIVE 
 
1. To evaluate the clinicopathological profile of haemophagocytosis 
diagnosed in the bone marrow in the Department of Pathology during 
the study period. 
2. To correlate the clinical, biochemical and other haematological 
parameters of these patients with the findings in the bone marrow.  
3. To highlight the haemophagocytic activity in bone marrow trephines 
using CD 68, an immunohistochemical marker for macrophages. 
4. To elucidate the aetiopathogenesis of this diverse disorder. 
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REVIEW OF LITERATURE 
 
HAEMATOPOIESIS: 
Each of the blood cells have a distinctive morphology and a specialized 
biological function. Erythrocytes are anucleate cells that contains haemoglobin 
and plays an important role in oxygenation of tissues. Granulocytes and 
monocytes are phagocytic cells which leave the circulation and migrate into 
tissues to perform their respective functions. B lymphocytes provide immunity 
by production of the antibodies while the T lymphocytes have a large variety of 
immune functions including killing of the cells that bear foreign molecules on 
their surface. Platelets are also anucleate cells which contains many enzymes 
that play an important role in haemostasis. Though all these cells have 
extensive differences in their morphology and function there is strong evidence 
that they all originate from a single progenitor called the hematopoietic stem 
cell (HSC). 
The process of haematopoiesis begins early during embryogenesis and 
undergoes many changes during the foetal and neonatal period. Unlike few of 
the other cells in the body which after maturation do not undergo mitosis or 
replenishment, the haematopoietic cells are continually replenished by the 
ongoing process of haematopoiesis. The period and the rate of replenishment of 
each cell depends on the life span of the particular cell. For example 
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erythrocytes have a life span of 120 days so the rate of erythropoiesis is less 
when compared to the WBC‟s which have a shorter life span. 
SITES OF HAEMATOPOIESIS: 
The process of haematopoiesis begins early in the gastrulation stage of 
the embryo in the extra embryonic yolk sac and the aorta gonad mesonephros 
(AGM). The process in the yolk sac is called primitive haematopoiesis since it 
produces erythrocytes, platelets and macrophages before the development of 
the circulatory system. From the yolk sac haematopoiesis shifts to liver and 
finally to bone marrow by the process of mobilisation and homing of stem 
cells. Although bone marrow is the active site for production of blood cells in 
children and adults, in adults it is restricted to the marrow of flat bones like 
vertebrae, ribs, sternum, etc. 
GENES CONTROLLING HAEMATOPOIESIS: 
Gene knockout experiments have opened a new insight into the study of 
genes controlling haematopoiesis. They are a process by which a particular 
gene is deleted from an experimental animal like mouse and the consequences 
of its absence are studied. By such methods genes controlling haematopoiesis 
like Bmp 4, VEGF,Tal-1/Scl, Gata-2 & RUNX-1 have been detected. In these 
the Bmp 4 and VEGF genes play important roles in primitive haematopoiesis 
and the embryos deficient in these genes die at an early gastrulation stage. 
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RETENTION AND HOMING OF HSC’s: 
As the process of haematopoiesis shifts from yolk sac to placenta then to 
liver and finally to bone marrow, the HSC‟s should migrate from one site to the 
other. The process of egress of HSC‟S from one site is called “mobilisation” 
and the directed movement towards the targeted site and retention in the 
particular hematopoietic organ is called “homing”.  
There are several factors which help in the egress and homing of 
HSC‟S. They are selectins, integrins, chemokines and the stroma of the 
haematopoietic organs.  
The selectins are the L, P and E selectins. They like in acute 
inflammation help in margination, rolling and adhesion of the HSC‟s to the 
endothelium. 
The integrins help in homing and retention of HSC‟S in the 
extravascular compartment. They are transmembrane receptors that transmit 
signals from the stroma to the cell and vice a versa.  
Chemokines like CXCL12 secreted by the bone marrow stroma bind 
with the ligand CXCR4 on the HSC‟s which directs them towards the bone 
marrow and helps in the process of homing. 
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STEM CELL NICHES: 
Once the HSC enters the bone marrow by the process of homing it 
migrates and aggregates in specialised areas called „niche‟s. This is a 
specialised microenvironment in the bone marrow which helps in maintenance 
of stem cells. The proposed cells which aid in the maintenance of stem cell 
niche‟s are the osteoblasts(3) , endothelial cells(4), mesenchymal lineage cells 
and non myelinating Schwann cells 
(5)
. 
GROWTH FACTORS IN HAEMATOPOIESIS 
There are several growth factors that play an essential role in division 
and maturation of cells in hematopoiesis. They can be multilineage that is they 
enable growth of  multiple lineages or lineage specific where they enable the 
growth of only a single lineage. Examples of growth factors are GM-CSF, G-
CSF, CSF-1, IL-3, IL-4, IL-6, IL-11, IL-12 and TPO
(6)
.  
PROCESS OF HAEMATOPOIESIS 
COMMITTED HAEMATOPOIETIC PROGENITOR CELLS: 
The process of haematopoiesis starts with HSC. The distinctive feature 
of a HSC is self renewal. But as the stem cells mature, each successive stage 
has a restricted differentiation potential. The HSC will differentiate to form 
multilineage progenitors. 
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MULTILINEAGE PROGENITORS: 
These are the first committed progenitors which lose the property of self 
renewal. There are multiple commitment steps and in each of these steps there 
is specific loss of lineage potential in a particular order. In the first step there is 
division into lymphoid and myeloid. Then myeloid differentiates into erythroid, 
megakaryocyte (CFU-MK), granulocyte, macrophage (CFU-GM) and so on. 
SINGLE LINEAGE PROGENITORS: 
They are descendants of multilineage progenitors and are ultimately 
related to only one lineage. It is until this stage they are all morphologically 
similar and differentiation can be made only with immuno histochemical 
markers. 
TERMINAL PHASES OF DIFFERENTIATION 
These cells are sufficiently differentiated that they are morphologically 
distinct. Although they are capable of only few divisions they undergo dramatic 
changes which help them differentiate and perform distinct functions. 
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HAEMATOPOIESIS 
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NK CELL 
Natural killer cells (NK cell) are cells of haematopoietic origin 
belonging to the lymphoid lineage. Since they lack the antigen receptor 
rearrangement of lymphocytes, these cells play an important role in innate 
immunity rather than adaptive immunity. This means that they do not require 
any pre-activation to recognise antigens to perform their function. 
ORIGIN 
NK cells are produced by the process of haematopoiesis. They develop 
from the common lymphoid progenitor (CLL) 
(1)
. The CLL cells then 
differentiate to form a NK cell progenitor and lymphoid progenitors. The 
common lymphoid progenitor expresses CD 117, CD 44 and NK1 but as they 
differentiate in to NK cell progenitors there is loss of CD 117 and there is 
acquisition of CD 2, CD 7 and CD 56.  
Initially the immature NK cells express dim CD56 which is the major 
component of the blood NK cell constituting 2% to 6% of blood leucocytes  
and 10% to 15% of peripheral blood lymphocytes.
(7)
 . Their main function is 
cytotoxic activity. 
Later the NK cell matures with a bright CD 56 expression. This 
constitutes the major NK cells in tissues like in lymph node, spleen, thymus 
and the uterine decidua
(8)
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CD 56 (dim) CD 56( bright) 
Immature  Mature 
Seen in peripheral blood Seen in lymph node , spleen & thymus 
Main function is cytolysis Main function is production of 
cytokines 
 
 
 
CYTOKINES FOR PRODUCTION & MATURATION 
The cytokines that are involved in NK cell production, maturation and 
proliferation are IL-15, IL-2, IL-4, IL-12, IL-18 and IL-21. IL2 and IL 4 
activates and promotes proliferation of NK cells. IL 12 and IL 18 are secreted 
by dendritic cell and macrophages. They aid in the cytotoxic activity of the NK 
cells. IL 21 enhances functional capacity and maturation of NK cell. 
MATURE NK CELL (ORGANS)
CD 56(bright) with increased production of cytokines
IMMATURE NK CELL(BLOOD)
CD 56(dim) with cytotoxic activity
NK CELL PROGENITOR
CD 2, CD 7, NK1.1
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MORPHOLOGY 
NK cells are nothing but the large granular lymphocytes (LGL). They 
have moderate pale blue cytoplasm with fine azurophilic granules. The nuclear 
cytoplasmic ratio is high with condensed chromatin and inconspicuous 
nucleoli. These cells like monocytes are positive for alpha naphthyl esterase 
with a diffuse staining of the cytoplasm in contrast to dot like staining in T 
lymphocytes. 
Ultra structurally they are heterogeneous. The granules are situated close 
to the golgi apparatus. They have an electron dense centre surrounded by a pale 
area. The granules as in T lymphocytes contain perforin and granzymes. These 
play an important role in cytotoxic effects of NK cells. 
NK CELL RECEPTORS 
There are three main groups
(1)
 of NK cell receptors called the  
1. Leucocyte immunoglobulin like receptors  “KIRs” 
2. Leucocyte Ig like receptors “LIRs” 
3. C- type lectin like receptors 
All these receptors have an extracellular ligand binding site and an 
intracellular cytoplasmic domain. The cytoplasmic domain can be long or 
short, inhibitory or activating site respectively. 
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The ligand for KIRs are HLA A, B or C and for C type lectins is HLA 
E. Whenever there is a binding of the receptors to the corresponding ligands 
there is either an activating signal or an inhibitory signal. In case of activating 
signals there is intracytoplasmic activation of immunoreceptor tyrosine based 
activating motif (ITAM) which enhances NK cell function. When there is an 
inhibitory signal there is activation of immunoreceptor tyrosine based 
inhibitory motif (ITIM) which inhibits NK cell activity. 
  INHIBITORY 
RECEPTORS 
ACTIVATING 
RECEPTORS 
LIGAND MHC 1
(8) 
 
Viral molecules and 
stress induced proteins
(8)
 
SIGNALS  Via ITIM motifs Via ITAM motifs 
FUNCTION For NK cell licensing 
For NK cell cytotoxic 
activity 
 
FUNCTION OF NK CELL 
NK cell plays an important role in the immune function of the body.  
Immunity is classically defined as “Protection from infection”(9). There 
are two broad categories of immune system in human body. They are innate 
immunity and adaptive immunity.  
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Innate immunity is immunity which does not require prior exposure. 
Here the cells are ready to react even before an infection occurs and it is the 
first line of defense. 
 Adaptive immunity develops following exposure to a particular 
pathogen. Since adaptive immunity is highly specific for a particular pathogen 
it is much more powerful and specific than innate immunity. 
The components of innate immunity are:   
a. The epithelium of skin, gastrointestinal tract, respiratory and 
genitourinary tract 
b. Monocytes and neutrophils 
c. Dendritic cells 
d. Complement system and 
e. NK cell 
Thus the NK cell forms a part of the innate immune system and plays an 
important role in the body‟s first line of defense. 
MISSING SELF HYPOTHESIS
 
 
The major breakthrough in the function of NK cell is the proposal of 
“Missing self” hypothesis. It explains that normally cells express host specific 
MHC 1 molecule. This is expressed by almost all cells in the body. When a cell 
expresses MHC 1 it is recognised by the inhibitory receptor of the NK cell 
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which down regulates its function and prevents destruction. But when there is a 
loss of MHC 1 molecule as in case of virus infected cell or tumour cells, NK 
cell recognises these cells as foreign and destroys these cells. This is called the 
missing self hypothesis. 
SPECIFIC NK CELL FUNCTION 
The cytotoxic function of NK cells plays an important role in two places. 
 lysis of virus infected cells 
 lysis of tumour cells. 
The NK cell performs its function of cytotoxic effect through three main 
pathways 
1) Perforin and granzyme mediated lysis 
2) Death receptor mediated lysis 
3) Antibody dependent cell mediated cytotoxicity 
1) PERFORIN & GRANZYME MEDIATED LYSIS: 
The NK cell contains membrane bound granules which contain the two 
important enzymes called granzyme and perforin. Whenever NK cell 
encounters a virus infected cell or a tumour cell both with loss of MHC 1 
molecule, it is activated. The granule contents are released by the process of 
exocytosis. The perforin present in the granules makes a pore in the target cell 
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and the granzyme enters the opponent cell to cause cell lysis by the process of 
apoptosis. 
2) DEATH RECEPTOR MEDIATED LYSIS 
The virus infected cells express the death receptor (Eg; CD 95/FAS). 
Death receptors belong to TNF family of receptors. They possess an 
extracellular ligand binding site and a protein-protein interacting cytoplasmic 
domain called the death domain
(9)
 .These death receptors are recognised by the 
cognate ligands in NK cell
(10)
. When there is engagement of these receptors 
three or more molecules of death receptors are brought closer to form FAS-
associated death domain ( FAS-DD). This FAS-DD then binds pro-caspase and 
cleaves it to form activated caspase. Once pro-caspase 8 is activated it sets up 
an enzymatic cascade in which one enzyme activates another and there is 
subsequent activation of the successive enzymes.  The subsequent caspases 
which are activated are caspase 3, 6. These caspases act on many of the cellular 
components like DNA and cause cleavage. It acts on nucleus to cause nuclear 
fragmentation and finally there is death of cell by the process of apoptosis. 
3)ANTIBODY DEPENDENT CELL MEDIATED CYTOTOXICITY 
(ADCC) 
The NK cell in addition to CD 56 also expresses CD 16 on its cell 
membrane. CD 16 is a receptor for Fc portion of the IgG antibody. Hence the 
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NK cell is able to recognise and bind the IgG coated target cells and cause cell 
lysis. This is termed as the antibody dependent cell mediated cytotoxicity. 
INTERACTIONS OF NK CELL WITH DENDRITIC CELL & 
CYTOTOXIC T LYMPHOCYTE (CTL) 
NK cell secretes cytokines like IFNγ. This IFNγ stimulates dendritic 
cells which in turn activate the CTL.  Also killing of tumour cells by NK cells 
and CTL increases the amount of antigen presentation by dendritic cells and 
hence enhance the adaptive immunity
(11)
. However the outcome of these 
reactions depends on the maturity of the dendritic cell. Immature dendritic cells 
are killed by NK cells but mature dendritic cells are resistant to lysis. These 
interactions take place mainly at the site of infection. The other place where 
they encounter each other is in the lymph node. 
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MACROPHAGES 
Macrophages form a part of the mononuclear phagocytic system. Elie 
Metchnikoff won the Nobel prize in 1908 for the discovery of macrophages.
(11)
 
They play an important role in host defense & also in tissue repair 
ORIGIN AND DEVELOPMENT OF MACROPHAGES 
Macrophages are also derived through the process of haematopoiesis. 
Haematopoiesis produces monocytes which are released into the circulation. 
These circulating monocytes enter tissues to differentiate into macrophages. 
The life span of macrophages ranges from months to years which is longer than 
that of the circulating monocytes.
(12)
 There are two different type of 
macrophages. – the tissue or the resident macrophages and the monocyte 
derived macrophages.  
The tissue macrophages are derived early in the embryonic and foetal 
period from the yolk sac and liver respectively
(9)
. These macrophages after they 
are produced, migrate to the respective tissues to form the permanent or the 
tissue resident macrophages. Examples are the astroglial cells in brain, Kupffer 
cells in the liver, osteoclasts in the bone marrow etc. 
The monocyte derived macrophages, produced by the process of 
haematopoiesis subsequently migrate to tissues to form macrophages.  This is 
called steady state production. Conditions like stress upregulate haematopoiesis 
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through increased production of granulocyte and monocyte stimulating factor 
which leads to increased production of macrophages.  
 
 
MORPHOLOGY 
Macrophages have a varied morphology. They are usually large rounded 
or stellate, with vesicular nucleus and conspicuous nucleoli. The cytoplasm has 
a well organised cytoskeleton, intracellular organelles and abundant lysosomes. 
CELL SURFACE RECEPTORS
(13)
 
The cell surface receptors help macrophages perform their function. The 
most important are the Pattern Recognition Receptors (PRR‟s). There are two 
types of PPR‟s. The first type is mannose receptor and scavenger receptor 
which helps in the process of phagocytosis
(14)
.
 
The second is the Toll like 
receptors which help in the recognition of microbes or damaged tissues.
(15)
 
EMBRYONIC 
/FETAL PERIOD
YOLK SAC/ LIVER
TISSUE RESIDENT 
MACROPHAGES
ADULT 
BONE MARROW
(HAEMATOPOIESIS)
INFLAMMATION 
MEDIATED
MACROPHAGES
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FUNCTIONS 
The main functions of macrophages are 
1) PHAGOCYTOSIS(9) 
The macrophages ingest and eliminate microbes and damaged tissues by the 
process of phagocytosis. This process of phagocytosis involves three main 
steps 
a) Recognition of microbes or dead tissues: This is done with the help of 
the receptors like the Toll like receptors which recognise and bind the 
inciting agent. 
b) Engulfment:  after the binding of the inciting agent cytoplasm extends to 
encircle the particle, the plasma membrane then pinches off to form the 
phagosome. 
c) Intracellular destruction: once the phagosome is formed it fuses with the 
lysosomes to form the phago-lysosome. Inside the phagolysosome the 
destruction is mediated by numerous factors like reactive oxygen 
species(ROS), reactive nitrogen species and the lysosomal enzymes, 
thus finally the inciting agent is destroyed and removed by macrophages 
2) TISSUE REPAIR 
Macrophages helps in tissue repair and fibrosis by production of certain 
cytokines like transforming growth factor beta ( TGF-β). 
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3) INFLAMMATION 
Macrophages secrete mediators of inflammation like tumour necrosis factor 
(TNF), and interleukin 1(IL 1).  
4) ANTIGEN PRESENTATION 
Macrophages also play a role in innate immunity. They recognise and 
present the antigens to the T lymphocytes and also respond to signals from 
the T lymphocyte 
MACROPHAGE ACTIVATION PATHWAYS 
There are two pathways of macrophage activation 
 Classical pathway & 
 Alternate pathway 
Accordingly there are three types of macrophages 
 M1 macrophages which are activated by the classical pathway 
 M2 which are activated by the alternate pathway and 
 The regulatory macrophages(16) 
M1 MACROPHAGES 
In the classical activation pathway the macrophages are stimulated by 
two important cytokines, interferon gamma (IFN γ) and tumor necrosis factor 
(TNF) which are secreted by NK cells and T lymphocytes. Thus they can be 
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stimulated either by innate immunity or adaptive immunity. The cytokines 
which are produced activate macrophages to form M1 macrophage. M1 
macrophages help in phagocytosis and microbicidal activity. They also produce 
certain cytokines like IL-1, IL-12 and IL-23 which recruit inflammatory cells 
and further enhance the inflammatory process.
(17) 
M2 MACROPHAGES 
In alternate activation pathway certain cytokines like IL-13 and IL-4
(18)
 
secreted mainly by the mast cells and basophils activate macrophages to form 
M2 macrophages. These macrophages produce enzyme arginase which 
produces TGF-β that helps in the production of extracellular matrix. Thus these 
M2 macrophages play an important role in tissue repair and fibrosis. 
REGULATORY MACROPHAGES 
These macrophages like the M1 macrophages can be stimulated by both 
innate and adaptive immune system.
 (19)
 TGF-β and immune complexes helps 
in the switch over to regulatory macrophages. These secrete many cytokines 
most importantly IL-10. This is an anti inflammatory cytokine which helps to 
sustain the process of inflammation and prevents tissue damage. 
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MACROPHAGE NK CELL INTERACTION 
NK cells of the innate immune system secrete cytokines like IFN-γ. This 
leads to stimulation of macrophages to form M1 macrophages when an antigen 
is encountered. The M1 macrophages serve to eliminate the antigen by the 
process of phagocytosis and also produce cytokines which enhances the 
process of inflammation. When there is defective NK cell function, it is not 
able to perform its function and there is persistent activation of NK cell and 
production of IFN- γ. This causes uncontrolled activation of macrophages 
which leads to untoward action of macrophages like haemophagocytosis. This 
forms the basis for the pathogenesis of Haemophagocytic syndrome. 
 
 
NK CELL
IFN-γ
TISSUE 
MACROPHAGES
M1 
MACROPHAGES
MICROBICIDAL 
ACTIVITY
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HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS 
 Haemophagocytic lymphohistiocytosis (HLH) also called 
Haemophagocytic syndrome is not a single disease. It is a syndrome which can 
manifest in numerous disease conditions. It consists of series of clinical 
symptoms, signs and laboratory manifestations which occurs due to defective 
NK cell activity leading to uncontrolled activation of macrophages resulting in 
haemophagocytosis. Defective NK cell activity and uncontrolled macrophage 
activation forms the hallmark of Haemophagocytic syndrome. 
INCIDENCE 
Estimated incidence of haemophagocytic syndrome is 1.2 cases per 
million individuals per year 
(20)
. This is most likely an underestimate because 
many cases remain undiagnosed and few are not reported. 
TYPES 
HLH is broadly categorised into two forms: Familial (FHL) or Primary 
HLH and Secondary HLH(s HLH).  This delineation into primary and 
secondary forms is just an over simplification because there is always a 
considerable overlap in many cases between the familial and the secondary 
forms. 
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CAUSES 
(20)
 
Primary HLH is mainly due to defects in genes involved in normal NK 
cell activity. It can be any of the genes which are involved in the production, 
transport or export of perforin granules involved in NK cell mediated lysis of 
target cells. 
Secondary HLH can be due to numerous causes as varied as infections, 
auto immune disorders and malignancies. 
PRIMARY HLH 
(21)
 
FAMILIAL HLH1 (FHL1) 
It was originally discovered in Pakistani families. It is linked to 
chromosome 9q21.33-22. The defect underlying the mutation is unknown. 
FAMILIAL HLH2 (FHL2) 
It was initially discovered in Turkish families. More than 70 different 
mutations have been identified. The most common mutation is linked to the 
perforin gene (PRF1) at 10q21-22. This gene is involved in the production of 
perforin enzymes. Mutation in this gene leads to impaired or block in 
production of perforin enzymes leading to impaired function of NK cell 
mediated lysis of infected cells. 
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FAMILIAL HLH 3 (FHL3) 
This form of HLH is due to defect in gene UNC13D located on 
chromosome 17q25. Mutations are scattered throughout the gene mainly 
affecting the mRNA splicing. This mutation results in defective delivery of 
perforin and granzyme to the target cell resulting in defective NK cell mediated 
lysis. 
FAMILIAL HLH 4 (FHL4)
(22)
 
This type of HLH was initially described in Turkish and Kurdish 
families. It is due to defect in the gene STX (syntaxin)11 situated on 
chromosome 6q24. Defect in STX11 gene leads to defective degranulation of 
NK cells. However HLH occurring due to defective STX11 gene is milder 
when compared to FHL1 and FLH 2 
FAMILIAL HLH 5 (FHL5) 
Initial reports of this form of HLH were from families of Saudi Arabia. 
It is due to defect in mutation of syntaxin binding protein 2 (STXBP2) located 
on chromosome 19p. STXBP2 codes for the protein Munc18-2 which is 
involved in regulation of transport of vesicle to plasma membrane of the NK 
cell. 
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CHEDIAK HIGASHI SYNDROME (CHS)
(23)
 
CHS is a rare autosomal recessive disease characterised by recurrent 
pyogenic infections, oculocutaneous albinism and recurrent respiratory tract 
infections. In CHS there is defect in the gene LYST which leads to defective 
NK cell activity resulting in haemophagocytic syndrome. About 85% of 
patients with CHS syndrome in accelerated phase present with HLH. 
GRISCELLI SYNDROME (GS2) 
Griscelli syndrome is due to defect in gene RAB27A  resulting in 
defective NK cell activity. 
X LINKED LYMPHOPROLIFERATIVE DISEASE (XLP1 & XLP2) 
XLP1 and XLP2 are due to defects in gene SH2D1A and XIAP 
respectively . 
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FAMILIAL HLH 
SYNDROME INHERITANCE GENE PROTEIN 
FHL1 AR 9q21.3-22 Not known 
FHL2 AR PRF1 Perforin 
FHL3 AR UNC13D Munc13-4 
FHL4 AR STX11 Syntaxin11 
FHL5 AR STXBP2 Munc18-2 
CHS1 AR LYST LYST 
GS2 AR RAB27A RAB27A 
XLP1 XL SH2D1A SAP 
XLP2 XL XIAP XIAP 
 
SECONDARY HLH 
Secondary HLH can be due to many causes starting from infections, 
auto immune disorders to malignancies 
1)   MACROPHAGE ACTIVATION SYNDROME (MAS)
(24)
 
MAS  is a severe acute inflammatory syndrome which is often under 
diagnosed. Most of these cases present with a clinical picture of HLH. This 
form of HLH occurs secondary to autoimmune diseases like systemic juvenile 
idiopathic arthritis, rheumatoid arthritis, Kawasaki disease, Systemic lupus 
erythematosus, and Stills disease. Marked decreased expression of perforin in 
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the CD 8 and NK cell activity forms the pathogenesis of HLH occurring in 
MAS. 
2) HLH ASSOCIATED WITH INFECTIONS 
VIRUS ASSOCIATED HLH
 (25)
 
Epstein Barr Virus (EBV) Associated HLH
(26)
 
EBV is an oncogenic virus which is the most common virus involved in 
the pathogenesis of HLH. It is common in the East Asian population. The main 
cell involved in EBV associated HLH is CD 8 T cell. EBV infected CD 8 T cell 
expresses Latent Membrane Protein (LMP) which makes it resistant to killing 
by other cytotoxic T cells. These EBV infected T cells produce a wide variety 
of cytokines which can result in HLH. HLH occurring in EBV virus infected 
persons is very aggressive and the prognosis is bad when compared to other 
forms of HLH. 
Cytomegalovirus (CMV) Associated HLH 
Compared to EBV which occurs in immunocompromised individuals, 
CMV associated HLH occurs in normal healthy individuals. This occurs 
usually in patients with severe avian influenza ( H5N1). 
HIV Associated HLH 
It can occur in persons with HIV alone or in persons with associated 
opportunistic infections. It usually occurs late in course of the disease when the 
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CD4 counts fall below 150cells/cu.mm. Rarely it may occur as an initial 
manifestation in persons with HIV. 
Parvovirus Associated HLH 
There are many species of parvovirus that can cause HLH of which B19 
associated HLH has a better prognosis. It is more common in patients with 
hereditary spherocytosis who are infected by parvovirus B19. 
Dengue Associated HLH 
Dengue fever virus is a virus of the family Flaviviridae. It causes dengue 
fever. Dengue associated HLH usually occurs late in the course of the disease. 
The prognosis is bad therefore early diagnosis and interpretation is essential. 
Other viruses involved in HLH 
Adenovirus, parvovirus, influenza, measles, mumps, enterovirus, pox 
virus, Heptatitis A, B & C etc 
BACTERIAL ASSOCIATED HLH 
Tuberculosis associated HLH 
This is the most common bacterial infection associated with HLH 
accounting for about 25% of infection associated cases. 
Other bacterial infections associated HLH: 
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Campylobacter, Staphylococcus, Fusobacterium, Mycoplasma, Chlamydia, 
Leigonella, Salmonella, Rickettsia, Brucella, Ehrlichia and Borrelia 
FUNGAL ASSOCIATED HLH 
The fungi which can cause HLH are Candida, Crytococcus, 
Pneumocystis, Histolplasma and Aspergillus. It‟s more common in immune 
compromised individuals like AIDS patients, transplant receipients and 
lymphoma patients 
PARASITE ASSOCIATED HLH 
The parasitic infections associated with HLH are Leishmania, 
Toxoplasma, Plasmodium, Pneumocystis Strongyloides, Babesiosis and Scrub 
Typhus 
3) MALIGNANCY ASSOCIATED HLH
(27)
 
This HLH are divided into two groups 
1. HLH occurring before or during the treatment of malignancy like 
a. Acute lymphoblastic lymphoma 
b. Acute myeloid leukemia 
c. Multiple myeloma 
d. Germ cell tumour 
e. Thymoma 
f. Carcinomas: Hepatocellular, Prostate, Lung 
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2. HLH with a masked haemato lymphoid malignancy 
a. T/NK cell leukaemia 
b. Adult B cell lymphoma 
c. Large cell Anaplastic lymphoma 
4)  IMMUNE DEFICENCY ASSOCIATED HLH 
Common immunodeficiencies associated with HLH are 
 Severe combined immunodeficiency 
 Common variable immunodeficiency 
 Chronic granulomatous disease and 
 Stem/ bone marrow transplant 
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PATHOGENESIS 
(28)
 
Defective NK cell activity and persistent macrophage activation is the 
hallmark of the pathogenesis of Haemophagocytic LymphoHisticytosis (HLH). 
Natural killer cell as already mentioned plays an important role in innate 
immunity which is the first line of defence. The natural killer cells recognise 
the virus infected and stressed cells and mediate lysis through perforin and 
granzyme. 
Whenever an antigen enters the human body it is recognised by the 
antigen presenting cell or the NK cell which secrets cytokines like IL 1. 
Interleukin 1 causes activation of T cells. The T cells activate and differentiate 
into T helper cells 1(TH1). TH1 secretes cytokines which further mediates the 
removal of the antigen by NK cell mediated lysis. It also promotes 
phagocytosis by the macrophages. 
In HLH there is defective NK cell activity which is due to genetic 
mutations in familial HLH or acquired defects in secondary HLH. 
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NK cell in its cytoplasm contains membrane bound vesicles containing 
perforin and granzymes. These enzymes are transported to the plasma 
membrane and the contents are released by exocytosis. The perforin creates a 
hole in the plasma membrane of target cells whereas the granzyme enters the 
cell and causes lysis. 
ANTIGEN
RECOGNISED BY APC/NK 
CELL
STIMULATES T HELPER 
CELL
ACTIVATES TH 1 RESPONSE
SECRETES CYTOKINES 
( IL , TNF & IFN)
ACTIVATES MACROPHAGES, NK CELL 
& CYTOTOXIC T LYMPHOCYTES
REMOVAL OF ANTIGEN
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In FLH 1 and FLH 2 there is defective production of these enzymes. In 
FLH 3 there is defective delivery of these enzymes into target cells. In FLH 4 
and FLH  5 there is defective exocytosis of the granules containing these 
enzymes 
In acquired HLH there is an acquired defect in the function of the NK 
cell, the  mechanism of which remains unknown. 
When there is defect in NK cell activity there is persistence of the 
antigen which leads to uncontrolled activation of macrophages and outpouring 
of the cytokines which leads to hypercytokinemia.  The hypercytokinemic state 
explains the cause for all the various manifestations of the HLH syndrome. 
 
DEFECTIVE NK 
CELL 
ACTIVITY
PERSISTENT 
ANTIGEN
PERSISTENT T 
CELL 
ACTIVATION
HYPER 
CYTOKINEMIA
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Hypercytokinemic state further leads to accentuation of TH1 response. 
There is an increase in TH1 cytokines like TNF-α, IFN-γ and IL-18(29). IL1 and 
TNF-α are called pyrogens and they cause fever. In addition these cytokines 
stimulate macrophages to perform the untoward or the non physiologic act, 
haemophagocytosis which is not normally the function of macrophages. In 
addition to this untoward action, macrophages start proliferating in the 
reticuloendothelial system causing organomegaly. 
Hypercytokinemic state also leads to suppression of haematopoiesis and 
apoptosis of haematopoietic elements
(29)
 which along with haemphagocytosis 
leads to cytopenias. 
TNF-α, IFN-γ in addition cause inhibition of lipoprotein lipase. 
Lipoprotein lipase catalyses the conversion of triglycerides to fatty acids.  
Inhibition of this enzymes leads to increase in serum triglycerides.
(30)
 
Activated macrophages convert plasminogen to plasmin. Plasmin causes 
degradation of fibrinogen hence there is a decrease in serum fibrinogen 
levels
(31)
. The inflammatory cytokines and the endotoxins causes upregulation 
of heme oxygenase which is a heat shock protein. Heme oxygenase causes 
increased production of ferritin leading to hyperferritinemia
(32)
. 
In response to accentuated TH 1 response there is increase in soluble 
CD25. 
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CLINICAL FEATURES
(33)
 
SYMPTOMS AND SIGNS 
CONSTITUTIONAL SYMPTOMS 
The cardinal clinical features of HLH are fever, cytopenias and 
organomegaly most commonly splenomegaly. Although these are the cardinal 
features they are not specific since there are numerous conditions which can 
present with such symptoms and signs. 
The patients are generally very ill and require urgent intervention and 
treatment. The first presentation is fever which is persistent and prolonged.  
This is mediated by the two cytokines IL-1 and TNF-α. The temperatures are 
usually very high and do not respond to any form of treatment. Usually 
children have a history of preceding upper respiratory tract infection or enteric 
infection. However instead of resolution of the infection, it proceeds to produce 
HLH which is characterised by more constitutional symptoms.  
ORGANOMEGALY 
There is usually organomegaly most commonly splenomegaly because 
of which the person presents with abdominal distension. Palpation of the 
abdomen reveals an enlarged non tender spleen and sometimes an enlarged 
liver. There can be associated ascites and derangement of liver functions 
causing nausea, vomiting and loss of appetite. 
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NEUROLOGICAL MANIFESTATIONS
 (34,35)
 
Central nervous system manifestations are common in HLH. Patients 
present with a range of CNS symptoms ranging from irritability, lethargy, 
stupor, seizures, cranial nerve palsies, hypotonia, ataxia, meningismus, focal 
deficits, decreased level of consciousness or loss of consciousness. There can 
be diffuse peripheral neuropathy secondary to infiltration by macrophages. 
There can also be loss of vision owing to retinal haemorrhage or infiltration of 
optic nerve by the macrophages. 
CUTANEOUS MANIFESTATIONS 
Cutaneous manifestations like petechiae, purpura or a generalised 
maculopapular rash, erythroderma and panniculitis can occur. The incidence of 
cutaneous manifestations ranges from 6% to 65%.
(36) 
PULMONARY MANIFESTATIONS 
Patients can have respiratory manifestations like breathlessness, chest 
tightness and dyspnoea. Severe cases can present with acute respiratory failure 
with interstitial opacities in the radiograph. It is estimated that there is a high 
mortality (88% of cases) in patients presenting with respiratory failure and 
interstitial opacities.
(37)
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LABORATORY FINDINGS: 
CYTOPENIAS: 
The most common and consistent laboratory finding is cytopenias, that 
is decrease in blood cell counts which may be anaemia, leucopenia or 
thrombocytopenia. Of these, thromobocytopenia is very common and usually 
there is bicytopenia involving atleast two of the cell lineages. The diagnostic 
criteria for HLH involves bicytopenia with any two of the following: 
haemoglobin <10g/dl, platelets < 100* 10
9
/L or absolute neutrophil count less 
than <1.0* 10
9
/L. 
LIVER FUNCTIONS: 
Most patients present with deranged liver functions. Neonates with HLH 
can present with hydrops foetalis and acute liver failure. Deranged liver 
function can be attributed to the primary cause like infections or it can also be 
due to proliferation of macrophages in the hepatic sinusoids which can 
compress the hepatic parenchyma, secrete cytokines and cause inflammation of 
liver producing hepatitis. There is an increase in liver alanine and aspartate 
amino transferases. 
COAGULOPATHY 
Derangement of coagulation is called coagulopathy. About 95% of HLH 
patients present with disseminated intravascular coagulation (DIC).
(35)
. There is 
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usually a decrease in the level of fibrinogen due to excess activation of 
plasminogen which in turn degrades fibrin causing hypofibrinogenimia. The 
patient can present with bleeding or thrombosis. Laboratory  investigations 
reveals decreased fibrinogen levels and a prolonged thrombin time.  Fibrinogen 
levels <1.5g/L is diagnostic. When there is an added DIC, there can be 
prolonged thrombin time, activated partial thromboplastin time and even low 
platelet count. 
LIPID PROFILE 
There is increase in serum triglycerides causing hypertriglyceridemia . 
This is due to inactivation of the enzyme lipoprotein lipase by the cytokines. 
Serum triglyceride level of > 265mg/L is diagnostic. 
FERRITIN 
Ferritin levels are increased in HLH patients owing to upregulated 
function of the enzyme heme oxygenase. Hyperferritinemia is an important 
hallmark of infection related HLH or secondary HLH. Serum ferritin of > 
500microgram/ L is diagnostic. Since ferritin is an acute phase reactant, high 
ferritin levels can be seen in other acute and also chronic inflammatory 
conditions. Therefore high ferritin levels are not specific but can be used as a 
reliable indicator to assess the disease activity during diagnosis and treatment. 
However ferritin level of > 2,000ng/ ml is considered to be specific. 
(38)
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CSF ANALYSIS 
Analysis of cerebrospinal fluid shows elevated CSF protein and cell 
count of > 5 cells/µL which is considered diagnostic. Cytological examination 
of CSF fluid may also show evidence of haemophagocytosis. 
BONE MARROW EXAMINATION 
Examination of bone marrow may reveal haemophagocytosis. Bone 
marrow macrophages are seen engulfing the haematopoietic elements which 
can either be erythroid precursors or myeloid precursors or even platelets. 
While the normal function of a bone marrow macrophage is to phagocytose the 
nucleus of the erythroid precursors and to remove the apoptotic haematopoietic 
elements, the exaggerated function of macrophages in haemophagocytosis in 
engulfing even normal haematopoietic elements is considered as untoward and 
pathological. 
Haemophagocytosis can be more readily recognised in a bone marrow 
aspirate when compared to a bone marrow trephine. However it can be 
highlighted in the trephine with immunohistochemical stains for macrophages 
like CD 68. The immunohistochemical marker CD 68 increases the sensitivity 
of detecting haemophagocytosis because there have been cases where HLH 
was not detected in aspiration but was diagnosed in trephine biopsy.
(39)
 
The main differentiating feature of haemophagocytosis from normal 
phagocytosis is that in phagocytosis there is immediate destruction of the 
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engulfed material. On the other hand, in heamophagocytosis the engulfed 
elements remain inside the cytoplasm for some time before they are destroyed. 
Haemophagocytosis may be observed in reticuloendothelial system like 
liver, spleen, lymph nodes and also in fluids, peripheral nerves etc 
SOLUBLE CD25 
CD 25 is an important cytokine secreted by the activated TH1. Since 
there is accentuated activation of TH1 in HLH there is dramatic rise in sCD25 
levels. This is otherwise called soluble interleukin 2 receptor. A value of > 
2,400U/ml is diagnostic. This usually helps to differentiate HLH from 
infectious mononucleosis and pseudomonas infection
 (40)
 
 NK CELL ACTIVITY
 (41)
 
Low or absent NK cell activity is the hallmark of HLH. It can either be 
hereditary where it is due to mutations in genes responsible for the NK cell 
function or secondary. In secondary HLH the cause for defective NK cell 
function remains unknown.  
 NK cell activity can be measured using  
1. Cytotoxic assays 
2. Flow cytometry 
3. Degranulation assays 
4. Genetic diagnosis 
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1) Cytotoxic assays 
In this assay, chromium labelled NK cell sensitive target cells are 
incubated with the peripheral blood mononuclear cells obtained by Ficoll 
gradient separation. Lysis of target cells by the NK cells leads to release of 
chromium which can be quantified. However when there is a reduced number 
of NK cells this test becomes less specific and can give false positive results.  
2) Flow cytometry  
It is based on the detection of intracellular perforin in NK cells. This can 
be highlighted by immunostaining of the perforin granules. Reduced expression 
of perforin in the cytoplasm indicates defective perforin enzyme and hence 
defective NK cell function. 
3) Degranulation assays 
These are based on the fact that NK cell cytotoxicity requires exocytosis 
of the granule content in the lysosomes. During this process of exocytosis the 
lysosomal membrane fuses with the plasma membrane. The activated or 
functional NK cell expresses the lysosomal membrane protein CD 107. 
Expression of CD 107 indicates normal functioning NK cell. 
In this test initially the NK cells are treated with K562 or IL2 which 
stimulate the NK cell and cause exocytosis. The exocytosis can be detected 
using  IHC marker CD 107. 
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4) Genetic diagnosis 
There are certain mutations which are specific for certain familial HLH 
which can be detected by molecular diagnosis.  
DIAGNOSTIC CRITERIA  
The first diagnostic criteria for HLH were proposed in 1991 and later 
were modified in 2004. The current guidelines for the diagnosis of HLH is 
based on the recent 2004 revision. 
GUIDELINES 1991 
In 1991, diagnostic guidelines for HLH were presented by the Histiocyte 
Society. In 1991 a proposal was based on the common clinical laboratory and 
molecular presentations of HLH. Since HLH can have varied and even have 
atypical presentations, the criteria have been revised and a new 2004 criteria 
has been proposed. 
(42)
 
In the 1991 proposal even the molecular diagnosis by a specific 
mutation had to be supported by an extra clinical manifestation for a 
confirmatory diagnosis. In the 2004 diagnostic criteria, the presence of one 
specific mutation is confirmatory for diagnosis of HLH. 
The category of supportive criteria in the 1991 classification has been 
deleted from the 2004 classification.  In addition the 2004 classification spells 
out specific cut off values for the various laboratory parameters. 
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GUIDELINES 2004 
In the 2004 guidelines, either the presence of a molecular pathology 
consistent with HLH or the presence of five out of the eight proposed criteria is 
diagnostic of HLH. The molecular mutations specific for HLH include PRF1, 
UNC13D, STX11 and UNC18B at a minimum. When X linked 
lymphoproliferative disease is suspected additional mutations like 
SH2D1A/SAP and BIRCA4 should also be considered. Specific molecular 
testing for diseases like Chediak Higashi syndrome, Hermansky Pudlak 
syndrome or Griscelli syndrome 2 should also be looked for. 
The eight diagnostic criteria for HLH are fever, splenomegaly, 
bicytopenia, hyperferritinemia, hypertriglyceridimia, evidence of 
haemophagocytosis, increased soluble CD 25 and low or absent NK cell 
activity. 
But applying these criteria for cases of Macrophage Activation 
Syndrome (MAS)  occurring secondary to auto immune diseases like systemic 
juvenile idiopathic arthritis resulted in delay in diagnosis. So the histiocytic 
society has set up a separate criteria for MAS syndrome where they have cut 
down few criterias and have increased the cut off values for certain laboratory 
parameters like serum ferritin.   
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HLH DIAGNOSTIC CRITERIA, 1991 
Molecular diagnosis of Haemophagocytic Lymphohistiocytosis or X linked 
Lymphoproliferative syndrome(XLP) 
OR AT LEAST 3 OF 4  
Fever 
Splenomegaly 
Cytopenias (minimum 2 cell lines ) 
AND AT LEAST 1 0F 4 
Haemophagocytosis 
Increased ferritin 
Increased sILR alpha 
Absence or decreased NK cell activity 
OTHER INVESTIGATIONS SUPPORTIVE OF HLH  DIAGNOSIS 
Hypertriglyceridimia 
Hypofibrinogenimia 
Hyponatremia  
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Diagnosis of HLH can be established if either A or B is fulfilled
(43)
 
A. Molecular diagnosis consistent with HLH 
B. Diagnostic criteria for HLH - 5 out of 8 criteria 
1. Persistent fever 
2. Cytopenias (affecting two or more lineages in the peripheral 
blood) haemoglobin <10g/dl, platelets < 100* 10
9
/L or 
absolute neutrophil count less than <1.0* 10
9
/L  
3. Splenomegaly 
4. Ferritin ≥ 500ng/mL 
5. Hypertriglyceridemia and /or hypofibrinogenemia 
 Fasting triglycerides ≥  265mg/dl 
 Fibrinogen ≤ 150mg/dL 
6. Haemophagocytosis in bone marrow , spleen or lymph node 
No evidence of malignancy 
7.  Low or absent NK cell activity 
8.  Soluble IL-2 receptor ≥ 2400U/Ml 
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Classification of MAS in Systemic juvenile idiopathic arthritis (sJIA)
(44)
 
A febrile patient with sJIA is diagnosed with MAS if the following criteria 
are met 
Ferritin > 684ng/mL and any two of the following 
1. Aspartate transaminase >48U/L 
2. Platelet count ≤ 181000/µL 
3. Fibrinogen ≤ 360mg/dL 
4. Triglycerides > 156mg/ Dl 
 
DIFFERENTIAL DIAGNOSIS AND PITFALLS 
The main differential diagnosis of HLH is Systemic Inflammatory 
Response Syndrome (SIRS) due to other causes where the clinical presentation 
is almost similar. However demonstration of haemophagocytosis in bone 
marrow, liver or spleen establishes the diagnosis of HLH. 
In addition neonatal haemochromatosis, or metabolic diseases of 
children presenting with massive organomegaly and hypertriglyceridemia can 
be differentials – here also the evidence of haemophagocytosis in the 
lymphoreticular system can be helpful. 
(45)
 
HLH can be difficult to diagnose in patients with Kawasaki disease.
 (46)
  
The other differentials are Langherhan cell histiocytosis but there the 
proliferating histiocytes compared to HLH are monoclonal 
(47)
 and Leishmania 
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donovani where one sees Leishmania donovani bodies in bone marrow rather 
than haemophagocytosis. 
TREATMENT
(48) 
THERAPEUTIC BACKGROUND 
The first major achievement in the treatment of HLH came in 1994 
when etoposide and immunosuppressive agents were added in the treatment 
regimen of HLH. For patients with CNS complications intrathecal therapy was 
introduced. Following this there was drastic improvement in the prognosis of 
patients with HLH. Even though there was improvement in the clinical 
condition of the patient complete cure was established only after 
Haematopoietic Stem Cell Transplantation (HSCT). In 2004 a new regimen 
was introduced which added a few more drugs suggesting a symptom based 
approach. 
HLH- 94 TREATMENT PROTOCOL: 
HLH 94 protocol involved three stages of therapy: 
1) INITIAL THERAPY( 1-8 WEEKS) 
During first 8 weeks of therapy a combination of etoposide and 
dexamethasone were given. It was found that even with this regimen deaths 
were reported. Hence an intensive 8 weeks therapy with immunosuppressive 
agents was recommended. 
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2) CONTINUATION THERAPY (9- 24 weeks) 
Continuation therapy included the same regimen of immunosuppression 
with dexamethasone along with CSF analysis every four weeks. This was 
added because most of the deaths during continuation therapy were due to CNS 
complications. 
3) INTRATHECAL THERAPY 
If the CSF analysis during continuation therapy showed abnormalities 
intra-thecal medications were given. 
4) HSCT 
If patient remained unresponsive to treatment, haematopoietic stem cell 
transplantation was considered. 
HLH- 2004 THERAPEUTIC DESIGN 
The revised 2004 treatment regimen has few modifications compared to 
the 1994 regimen. It includes four therapies. 
1) INITIAL THERAPY  
Initial therapy involves using etoposide and dexamethasone for 8 weeks 
along with monitoring of CSF every 4 weeks .If the CSF analysis shows 
pleocytosis, intrathecal administrations are considered.
(49,50) 
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2) CONTINUATION THERAPY 
In patients without a molecular mutation and patients without a family 
history of HLH in whom there is improvement, the treatment can be stopped at 
this point. However, others are administered the continuation therapy until 
HSCT. 
3) REACTIVATION THERAPY 
Reactivations are common in HLH. The recurrence of HLH in patients 
with a previous history of HLH who were declared cured after treatment is 
called reactivation. Reactivation therapy is very intense compared to the initial 
therapy. It includes frequent intrathecal administrations. 
4) SALVAGE THERAPY 
Salvage therapy includes a combination of steroids, 
immunosuppressives and antithymocyte globulin. 
5) STOPPING THERAPY 
Stopping therapy is only recommended in patients with complete cure. 
But even then close monitoring of these patients for fever, blood counts and 
organomegaly is suggested. 
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HAEMATOPOIETIC STEM CELL TRANSPLANTATION 
The choice of the donor depends on the clinician. HLH matched sibling 
donor is preferred but even they should be investigated for HLH mutations 
before transplant. If no matched donor is available a haplo-identical family 
donor is suggested.
(51)
 
The preparative regimen and GVHD prophylaxis proposes using 
etoposide, busulphan and cyclophosphamide. 
The recommended marrow infusion is >3*10
8
nucleated cells/kg and non 
T cell depleted. It is recommended to use non T cell depleted because the donor 
T cells and NK cells are required for curing HLH. However when haplo-
identical donors are used T cell depletion is a must to prevent GVHD.  
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REGISTER , START 
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THERAPY UNTIL 
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CONTINUATION 
THERAPY UNTIL 
HSCT
RESOLVED NON 
FAMILIAL HLH
STOP THERAPY
REACTIVATION
CONTINUATION 
THERAPY UNTIL 
HSCT
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PROGNOSIS 
(48)
 
Survival for patients with HLH has drastically improved in the last 
decade after the above treatment regimens were put into practice and the advent 
of HSCT. The overall 3 year survival for HLH patients after HSCT is 64%. 
With HLA matched donors it is 71%, with matched unrelated donors 70%, with 
haplo-identical family donors it is 50% and with mismatched unrelated donors 
54%. In order to further improve the prognosis of patients with HLH clinical 
trials in the field of pathogenesis, diagnostic and therapeutic guidelines are 
required and recommended for the future. 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
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MATERIALS & METHODS 
This is a retrospective study. Cases of Haemophagocytosis reported in 
the bone marrows received in the Department of Pathology, PSGIMS & R 
during the period starting from January 2010 to May 2017 were taken. 
Information regarding the age, sex and clinical presentation of the patients were 
derived from the requisition forms sent along with the bone marrow aspirates 
and trephine biopsies as well as from the hospital information system.  
METHODS 
MATERIALS REQUIRED: 
 Salah‟s bone marrow aspiration needle 
 Jamshidi trephine biopsy needle 
 Clean glass slides of size 7.5*2.5* 0.1 cm 
 Methanol for fixation of smears 
 Giemsa staining solution 
SITE OF BIOPSY
 (52)
: 
 The posterior superior iliac spine is the preferred site.  
 In case of obese patients the anterior superior iliac spine or the sternum 
was taken. 
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PROCEDURE 
Under aseptic precautions and local anaesthesia the posterior superior 
iliac spine was palpated and the Salah‟s needle was inserted with a boring 
movement. The entry of the needle into the marrow was identified by the 
giveaway feel. Once inside the marrow the cannula was removed, a syringe 
was attached and the marrow contents were aspirated. 
After the process of aspiration, the bone marrow trephine biopsy needle 
(Jamshidi needle) was inserted and a core of bone marrow trephine was 
obtained. The specimen was placed in a container containing 10% neutral 
buffered formalin. 
PREPARATION OF SMEARS 
There are two methods for preparing a bone marrow aspiration smear 
1. Squash technique 
2. Smear technique 
In our institution we use the squash technique for preparing the smear.  
The bone marrow aspirate is placed on one end of the slide and with a help of 
another slide the material is squashed between the two slides to obtain the 
smear. 
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STAINING OF BONE MARROW ASPIRATE SMEARS 
PROCEDURE: 
1. Fix smears in methanol for 30 minutes 
2. Air dry the smears 
3. Mix 1 part Giemsa solution with 3 parts buffered water of pH 7 
4. The smears are flooded in the staining solution for 20 minutes 
5. The stained slides are washed in running tap water 
6. The smears are allowed to dry 
7. Dipped in  xylene  
8. Mounted using DPX 
Once the slides are stained, the bone marrow aspirate is studied.  
PROCESSING OF BONE MARROW TREPHINE BIOPSY 
The bone marrow trephine biopsies were sent to histopathology 
laboratory in 10% neutral buffered formalin. They were decalcified using 
aqueous EDTA of  pH 7.6 . The blocks were processed and sections taken for 
H & E staining and immuno histochemical marker (IHC) studies. 
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HEMATOXYLIN & EOSIN STAINING
(53)
 
REAGENTS USED 
1. Xylene 
2. Iso propyl alcohol 
3. 1% acid alcohol 
4. Eosin Y  
5. Harris hematoxylin 
6. DPX 
PROCEDURE: 
1.  Deparaffinisation – xylene three changes 5 minutes each 
2. Hydration – graded concentration of iso propyl alcohol followed by 
water – 2 minutes each 
3. Progressive staining- Harris haemtoxylin for 15 minutes 
4. Bluing- running tap water  for 5 minutes 
5. Differentiation -  1% acid alcohol for 10 seconds, 
6.  Bluing – tap water for 10 minutes 
7. Counter staining- Eosin Y  for  2 minutes 
8. The stained slides are then washed in running tap water for three minutes 
9. Dehydration- increasing gradient of isopropyl alcohol 2 minutes each 
10. Clearing- Xylene 1 dip 
11. Mounting- with cover slip using resinous mounting media DPX. 
The stained slides were then studied.  
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IMMUNOHISTOCHEMICAL STAINING  
(54)
 
The blocks were cut at 5 micron thickness and the sections were taken 
onto Poly L lysine coated slide. 
REAGENT USED 
Antibody reagent Clone 
CD 68 
Monoclonal mouse antihuman 
antibody 
Clone: KP1 
 
PRINCIPLE 
The staining process involves two steps: 
1. Binding of the specific primary antiboby to the target epitope. 
2. Identification of the primary antibody using a secondary antibody by a 
colorimetric reaction. 
ANTIGEN  RETRIEVAL 
Fixation in formalin leads to masking of certain antibodies due to cross 
linking of proteins. These antigenic sites can be exposed using the antigen 
retrieval technique. 
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There are three methods for antigen retrieval: 
1. Pressure cooker method 
2. Microwave method 
3. Proteolytic digestion method 
The antigen retrieval for the material in this study were done using the 
pressure cooker method. Before antigen retrieval, the slides were dewaxed with 
xylene and hydrated in graded alcohols. The slides were then placed in a silver 
trough containing Tris-EDTA buffer at an alkaline pH of 9 which was 
preheated to boiling point using a pressure cooker. The lid was then sealed and 
the slides were incubated in the pressure cooker for 15 minutes. 
 REAGENTS USED 
1.  Ethylene Diamine Tetra Acetic acid ( EDTA) buffer at ph 9 
2. 0.01M Phosphate Buffered Saline (PBS) at a pH of 7.6. It is prepared by 
mixing di-basic sodium phosphate- anhydrate 17.5 g, sodium chloride 
17.0 g and monobasic potassium phosphate- anhydrate 2.5 g in one litre 
of distilled water. 
3. 3% hydrogen peroxide which blocks the endogenous peroxidase and 
hence prevent background staining. 
4. Blocking reagent- Caesin with 15mM sodium azide which helps in 
blocking the non specific protein binding. 
5. Primary antibody- CD68 
62 
 
6. Horse Radish Peroxidase enzyme 
7. Chromogen- DAB ( 3,3‟ DiAmino Benzidinetetrachloride) which is 
responsible for the brown colour. 
8. Harris haematoxylin – counter stain 
9. DPX- mountant 
PROCEDURE 
1. Dewax – xylene 
2. Hydration- in graded alcohols 
3. Antigen retrieval- in EDTA buffer at an alkaline pH 9 in the pressure 
cooker for 15 minutes. 
4. Washed in running tap water 
5. Washed in PBS for 5 minutes 
6. Immersed in hydrogen peroxide for blocking of the endogenous 
peroxidase. 
7. Washed in PBS three times for 5 minutes. 
8. Diaminio Benzidine used for eight minutes. 
9. Incubated in blocking solution for ten minutes. 
10. Washed in PBS buffer three times 5 minutes each. 
11. Slides incubated with CD 68 primary antibody for one hour. 
12. Washed with PBS buffer three times for 5 minutes 
13. DAB for eight minutes 
14. Washed with PBS buffer three times for 5 minutes. 
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15. Counter stained with Harris hematoxylin for 15 minutes. 
16. Washed in running tap water 
17. Cleared with xylene 
18. Mounted using DPX 
 The stained slides are then screened for macrophages which demonstrate 
haemophagocytosis. 
DATA ANALYSIS 
The data for this study was collected using the patient requisition forms, 
hospital information system and discharge summary of the patients. 
The parameters documented were: 
1. Age of the patient 
2. Fever 
3. Splenomegaly 
4. Blood counts 
5. Triglycerides levels 
6. Fibrinogen levels 
7. Ferritin levels 
8. Bone marrow findings 
9. Investigations relevant to the pathology underlying the 
haemophagocytosis. 
The information was entered into a Microsoft Excel worksheet and 
extrapolated into statistical package. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results and Observation  
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RESULTS AND OBSERVATIONS 
32 cases that presented with Haemophagocytosis in the bone marrow 
during the period January 2010 to May 2017 were studied. The age, clinical 
presentation like fever, splenomegaly, laboratory parameters like blood counts, 
ferritin levels, triglyceride levels and fibrinogen levels were analysed. 
AGE DISTRIBUTION 
Of the 32 cases in our study 62% of cases were in the adult age group 
(>18 yrs)  and  38%  were from the paediatric age group. 
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DIAGNOSTIC CRITERIA 
Of the eight criteria for diagnosis of HLH, CD 25 levels and NK cell 
activity were not performed in our laboratories. The other criteria like fever, 
splenomegaly, blood counts, ferritin levels, triglyceride levels and fibrinogen 
levels were analysed. 
The presence of haemophagocytosis in the bone marrow was taken as 
the criteria for selecting cases, hence 100% of the cases had morphologic 
evidence of haemophagocytosis. Where the rest of the criteria are concerned, 
100% of cases had fever, 53% had splenomegly, 78% had bicytopenia, 87% 
had hyperferritinemia, 59% had hypertriglyceridemia and 31 % had 
hypofibrinogenemia. 
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DIAGNOSTIC CRITERIA 
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CYTOPENIAS 
78% of cases in our study presented with bicytopenia. The 
haematological parameters are again graded based on the severity 
(54)
. 
Haemoglobin levels are graded into normal (>12 g/dl), mild to moderare 
anaemia (7-12 g/dl %) and severe anaemia (<6g/dl). Total count is graded into 
those with leucopenia (<4* 10
9
/l), normal WBC count (4- 12 *10
9
/l) and 
leucocytosis (>12*10
9
/l). Platelet counts are graded as severe 
thrombocytopenia (<10*10
3
/µl), mild to moderate thrombocytopenia (10-
150*10
3
/µl), normal platelet count (150-450*10
3
/µl) and thrombocytosis 
(>450*10
3
/µl).  
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The results of the patients studied along with the grade of severity of the 
haematological parameters: 
 Hb (g/dl) Percentage of patients 
Severe anaemia < 6 12 % 
Mild to moderate anaemia 7-12 69% 
Normal >12 19% 
 WBC count (*10
9
/l) Percentage of patients 
Leucopenia <4 59% 
Normal leucocyte count 4-12 22% 
Leucocytosis >12 19% 
 Platelet 
count(*10
3
/µl) 
Percentage of patients 
Severe thrombocytopenia <10 12% 
Mild to moderate 
thrombocytopenia 
10-150 63% 
Normal 150-450 19% 
Thrombocytosis >450 6% 
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BLOOD COUNTS 
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BONE MARROW TREPHINE 
Of the 32 cases, 19% of cases presented with haemophagocytosis in 
both bone marrow aspirate and trephine, while the remaining 81% 
demonstrated haemophagocytosis only in bone marrow aspirate. There were no 
cases that were trephine positive but bone marrow aspirate negative. The 
haemphagocytic activity in the bone marrow trephine was highlighted using 
IHC marker CD 68. 
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TYPES OF HLH 
HLH is divided into two types - Primary HLH and Secondary HLH. 
Primary HLH includes cases which have a diagnostic molecular mutation. 
Secondary HLH includes cases which occur secondary to causes like 
infections, inflammatory conditions and even malignancies. 
Of the 32 cases in our study, 3 % cases were of Primary HLH and the 
remaining 97% were Secondary HLH. 
 
 
97%
3%
HLH TYPES
SECONDARY 
HLH 
PRIMARY HLH
72 
 
AETIOLOGY 
The most common aetiology for HLH in this study was infection which 
accounted for about 70 % of the cases. This was followed by cases of Non 
Hodgkins lymphoma which accounted for about 6 %. The rest of the cases 
were due to Myelofibrosis, Multiple myeloma, Myelodysplastic syndrome, 
Aplastic anaemia, Kikuchi Fujimotos disease, Chediak Higashi disease, and 
Systemic lupus erythematosus HLH each of which accounted for about 3% of 
the case. The remaining cases were primary HLH.  
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INFECTIONS 
Infection was found to be the most common cause for the HLH 
accounting for 70% of the cases.  
Bacterial infections accounted for 55%, viral infections were 28%, 
parasitic infestations 9%  and fungal  4%. In the remaining 4% the causative 
organism could not be isolated.  
Tuberculosis was the most common infection accounting for 23% of the 
cases due to infections.  The second most common cause was disseminated 
sepsis which accounted for 19%. Typhoid accounted for 15%, Dengue fever, 
Scrub typhus and HIV accounted for 9% totally.  Hepatitis A, Nocardial 
infection,Viral pneumonia and PUO were 4% each. 
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NEOPLASMS ASSOCIATED WITH HLH  
After infections, the most common cause for haemophagocytosis was 
neoplasm associated HLH accounting for 16% of the total cases. Lymphomas 
accounted for 40% of the neoplasm associated HLH. 20% of the cases had a 
diagnosis of Multiple myeloma The rest were Myelodysplastic syndrome and 
Myelofibrosis each accounting for 20 %. 
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NEOPLASM ASSOCIATED HLH 
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DEATHS ASSOCIATED WITH HLH 
Of the 32 cases, 19 % of cases had a very turbulent clinical course 
which resulted in the death of these patients. 
Of the deaths associated with HLH 32% were due to sepsis. Scrub 
typhus, hepatitis A, diffuse large B cell lymphoma & multiple myeloma 
contributed to 17% each. 
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Pictures  
 
 
 
 
 
Fig 1: Macrophages phagocytosing RBC’s 
 
 
 
Fig 2: Macrophages phagocytosing normoblasts & metamyelocytes. 
 
 
 
 
 
Fig 3: Macrophages phagocytosing platelets. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4: Haemophagocytosis in bone marrow trephine biopsy. 
 
 
 
 
Fig 5: Haemophagocytosis in trephine highlighted using 
Immunohistochemical marker CD 68. 
 
 
Fig 6: Haemophagocytosis in a patient with primary HLH. 
 
 
     
(a)                                                          (b) 
 
                      (c) 
Fig 7: (a & b) Cytoplasmic vacuolations in the erythroid precursors in 
bone marrow of an alcoholic patient with Hepatitis E infection.                                            
(c) Haemaophagocytosis in the bone marrow of same patient. 
 
 
 
    (a) 
 
     (b) 
Fig 8: (a) Granulomas in bone marrow of a patient with tuberculosis. (b) 
Erythrophagocytosis in bone marrow of the same patient 
 
 
 
 
(a)                                                       (b) 
Fig 9: Abnormal granules in the cytoplasm of WBC’s in peripheral smear 
of a patient with Cheidiak Higashi syndrome (CHS). (a) within 
lymphocytes (b) within neutrophils 
 
 
 (a) (b)                
Fig 10: (a)Abnormal granules in the cytoplasm of myelocytes in bone 
marrow of a patient with CHS. (b) Haemophagocytosis in the bone 
marrow of the same patient 
 
 
        
(a)                                                           (b) 
Fig 11: Haemophagocytosis(a) in a patient with Atypical lymphoid cells(b) 
in bone marrow diagnosed to be DLBCL. 
 
       
Fig 12: Haemophagocytosis in a patient with aplastic anaemia showing 
acellular marrow spaces. 
 
 
 
         
(a)                                                                   (b) 
Fig 13: (a) Bone marrow trephine of a patient with myelofibrosis.                       
(b) Haemophagocytosis in the bone marrow of the same patient 
 
       
(a)                                                                (b) 
Fig 14: (a) Increased plasma cells in bone marrow of a patient with 
multiple myeloma (b) Erythrophagocytosis in bone marrow of same 
patient. 
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DISCUSSION 
Haemophagocytic lymphohistiocytosis is a syndrome rather than a 
single disease which can occur in numerous disease conditions. The estimated 
incidence of HLH is 1 in 1,00,000
 
live births.
(55)
 But this is just an under 
estimation because many of the cases  are under recognised. The primary HLH 
is more common in childhood while secondary HLH can occur at any age. 
This study was done with the aim of elucidating the various 
aetiopathogenesis of HLH. Awareness of the various aetiologies of this 
important entity will go a long way in helping to make an early diagnosis and 
promptly treat the patient. 
In the 32 cases we analysed 62% were of the adult age group (>18yrs) 
and the remaining 38% of the paediatric age group (<18 years) with a mean age 
of presentation of 30.7 yrs. This was in correlation with a study by Iqbal et al 
who found the mean age of presentation of HLH to be 30.8 years.
 (56)
 
The difference between the presentations in males and females was not 
found to be significant. This is similar to what has been stated by Iqbal et al. 
Taking in to account the diagnostic criteria, fever was the most common 
clinical presentation in our study. Melissa et al observed that almost 100% of 
HLH cases presented with fever
(55)
 while Iqbal et al stated that 65.2% of cases 
presented with fever. 
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Our study was in correlation with Melissa et al where all 100% of cases 
presented with fever thus concluding that the most common presentation of a 
patients with HLH is prolonged and persistent fever unresponsive to therapy.  
The diagnostic criteria of splenomegaly was observed by Iqbal et al in 
37.2% of patients while Laurence et al observed splenomegaly in 65% of cases 
(57)
. Melissa et al stated that an enlarged spleen was present in 100% of patients 
with primary HLH and 80-90%  in secondary HLH.  
In our study splenomegaly was present in 53% of cases. This result 
approximately correlates with what was seen by Laurence et al. 
Melissa et al observed cytopenias in 80% of cases, Iqbal et al have 
graded the cytopenias and have given percentages accordingly. 
HAEMOGLOBIN LEVELS 
 Hb (g/dl) Iqbal et al This study 
Severe anaemia < 6 29 % 12 % 
Mild to moderate anaemia 7-12 66 % 69% 
Normal >12 11% 19% 
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WBC COUNT 
 
WBC count   
(*10
9
/l) 
Iqbal et al This study 
Leucopenia <4 34% 59% 
Normal leucocyte count 4-12 26% 22% 
Leucocytosis >12 55% 19% 
 
 
PLATELET COUNT 
 
Platelet 
count(*10
3
/µl) 
Iqbal et al This study 
Severe 
thrombocytopenia 
<10 2.4% 12% 
Mild to moderate 
thrombocytopenia 
10-150 70% 63% 
Normal 150-450 64% 19% 
 
 
COMMON PRESENTATION 
 Iqbal et al This study 
Hb levels 
Mild to moderate 
anaemia 
Mild to moderate 
anaemia 
WBC count Leucocytosis Severe leucopenia 
 
Platelet count 
Mild to moderate 
thrombocytopenia 
Mild to moderate 
thrombocytopenia 
82 
 
Mild to moderate anaemia was common in both the above studies. 
Leucocytosis was found to be common in HLH cases studied by Iqbal et al. In 
contrast to this we observed severe leucopenia in our study. As was in the case 
of the haemoglobin levels mild to moderate thrombocytopenia was found to be 
common in both the studies. 
Ferritin levels are an important indicator of the degree of phagocytic 
activity of macrophages
(38)
. Melissa,et al observed hyperferritinemia in70-
90%of cases, while Chandra et al observed this abnormal parameter in only 
40% of cases
(58)
.In our study hyperferritinemia was found in 87% of cases 
which correlates with the observations  of Melissa et al. 
Laurence et al observed that ferritin levels of >2,000ng/ml were more 
diagnostic of HLH which was also observed in our study. Neelima et al in their 
study observed that ferritin levels more than being a diagnostic criteria acts 
better as a prognostic indicator in patients on treatment with the HLH regimen. 
Hyperferritinemia of >2000ng/ml therefore appears to be diagnostic of HLH 
and also serves better as a prognostic factor in patients on treatment.  
Melissa et al observed hypertriglyceridemia in 40% of cases while 
Chandra et al observed abnormal lipid levels in 45% of cases. Our study had 
59% of HLH cases presenting with hypertriglycerdemia. 
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Melissa et al and Chandra et al both observed 40% of cases presenting 
with hypofibrinogenemia. Similar results were observed in our study which had 
31% of the cases presenting with low fibrinogen levels. 
Caleb Ho et al used the IHC marker CD 68 to highlight 
haemophagocytosis in bone marrow biopsies. This helped in increasing 
sensitivity and enabled quantification of haemophagocytic activity in trephine 
biopsies.
(39)
. However, in our study, using the marker CD 68 on trephine 
biopsies did not help to increase the sensitivity of detection of abnormal 
phagocytic activity.  
The HLH essentially is divided into primary HLH and secondary HLH. 
Primary HLH is more common in children usually less than one year of age. 
Ling et al have stated that primary HLH accounted for 25% of the HLH 
presenting in the paediatric age group
(59)
. In our study HLH in the paediatric 
age group was 38%. However the percentage of primary HLH amongst these 
cases was only 3%.This can be attributed to the our lack of facilities for the 
diagnosis of molecular mutations and the economic constraints of the study 
population. 
In our study the most common cause for secondary HLH was infection 
which accounted for 70% of the total cases. Melissa et al stated 50% while 
Chandra et al observed 13% of infection associated HLH. Though there is a 
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difference in the percentage of cases, in all three studies infection associated 
HLH was the most common cause for secondary HLH. 
Among infections Ling et al observed bacterial infections to be the most 
common cause. While Chandra et al observed equal presentations amongst 
bacterial and viral infections, Melissa et al observed an increased incidence in 
viral infections contributing to HLH. 
 
Percentage of cases 
Ling et al Chandra et al This study 
Bacterial 46% 30% 55% 
Viral 41% 30% 28% 
Fungal 13% 20% 4% 
Parasitic - 20% 9% 
 
Amongst the bacterial infections tuberculosis was found to be the most 
common. This aetiological factor was observed in all the studies. ( Ling et al, 
Chandra et al & Tseng, et al). 
 
Percentage of cases 
Ling, et al Chandra, et al Tseng, et al
(60)
 This study 
Tuberculosis 23% 20% 25% 23% 
 
85 
 
Patel R et al stated typhoid as a very rare cause for HLH 
(61)
. In our 
study we had 15% of the infection associated HLH cases associated with 
typhoid. 
Ling et al observed EBV as the most common viral infection for HLH 
accounting for about 18% while in our study we had only 3% of EBV 
associated cases (one patient) who also had a coexsisting diffuse large B cell 
lymphoma. 
Sara et al observed 5% of HIV associated HLH
(62)
. Dengue and HIV 
associated viral infections was found to be more common in our study 
accounting for 9 % each of the cases of haemophagocytosis.  
Percentage of Viral Infection Associated HLH 
 Ling et al 
Ramachandran et 
al
(63)
 
This study 
Common infection EBV( 18%) Dengue virus(12%) 
HIV & 
Dengue(9% each) 
  
Chandra et al found malaria as the most common (20%) parasitic 
infection associated with HLH. In contrast in our study Scrub typhus was the 
most common parasitic infestation (9%).  
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Micheal et al 
(64)
 , Ling et al, Melissa et al observed that the second most 
common cause for secondary HLH is neoplasm associated HLH (both 
haematological and non- haematological). Among the malignancies lymphoma 
was the most common in all studies. 
In our study 16% of cases were due to malignancies (both 
haematological and non- haematological). Among them lymphoma was the 
most commonly observed (40%) diagnosis. This finding confirms to what has 
been observed above.  
MALIGNANCY ASSOCIATED HLH
(64)
 
STUDY 
No. of patients with 
malignancy associated 
HLH 
Most frequent 
associated malignancy 
Tamamyam et al
(65)
 35 AML/MDS 
Parikh et al
(66)
 32 T cell lymphoma 
Otrock & Eby et al
(67)
 21 B cell lymphoma 
Lehmberg et al
(68)
 21 T cell lymphoma 
Shabbier et al
(69)
 6 T cell lymphoma 
This study 5 B cell lymphoma 
 
 Chandra et al observed 3% of multiple myeloma patients presenting 
with HLH which was in correlation with our study also in which we found that 
3%  of cases with myeloma and haemophagocytosis.  
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Elena et al stated perforin gene mutations in aplastic anaemia can act as 
a aetio-pathogenetic factor for the subsequent development of HLH
(70)
. 
Chandra et al observed 3% of aplastic anaemia cases presenting with HLH 
which was in correlation with our study which also had 3% of aplastic anaemia 
associated HLH. 
Many immunodeficiency syndromes like Cheidiak Higashi syndrome, 
Hermansky Pudlak syndrome, Griscelli syndrome are all found to be associated 
with HLH. Amina et al states that 85% of Chediak Higashi syndrome patients 
in their accelerated stage present with HLH
(23)
. In our study we had 3% of HLH 
cases secondary to Chediak Higashi syndrome. 
Cesar et al observed that HLH secondary to autoimmune diseases 
requires special diagnostic criteria for its identification because of the varied 
presentations in such diseases. 
(42)
. 
Classification of HLH in autoimmune conditions
(42)
 
A febrile patient with a known auto immune disorder is diagnosed with 
HLH if the following criteria are met 
Ferritin > 684ng/mL and any two of the following 
5. Aspartate transaminase >48U/L 
6. Platelet count ≤ 181000/µL 
7. Fibrinogen ≤ 360mg/dL 
8. Triglycerides > 156mg/ Dl 
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 Using the above parameters as criteria for diagnosis Cesar et al 
observed that the most common autoimmune condition associated with HLH 
was SLE (15% )
(24)
. In our study we had 3% of SLE associated HLH cases.  
Nishiwaki et al states Kikuchi Fujimoto‟s disease as a rare cause for 
HLH. These patients present with lymphadenopathy. In all such cases, an 
underlying lymphoma associated HLH has to be ruled out before diagnosis 
(71)
.  
In our study we had a paediatric patient presenting with HLH secondary to 
Kikuchi Fujimoto‟s disease. 
Jan-Inge et al states that the three year survival for patients with HLH 
following haematopoietric stem cell transplants is 64%
(47)
. Melissa et al & 
Michael et al observed that recurrences are common and prognosis is bad for 
malignancy associated HLH. Likewise in our study 34% of deaths in HLH 
were due to malignancy followed by deaths due to sepsis which accounted for 
about 32%. 
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The conclusions drawn from the studies are as follows 
Entity compared 
Authors of 
the study 
Conclusion 
Conclusion from 
this study 
Mean age of 
presentation 
Iqbal et al 30.8 yrs 30.7yrs 
Sex distribution Iqbal et al Insignificant  Insignificant  
Fever Melissa et al Most common 
presentation(100%)  
Most common 
presentation(100%) 
Hb levels Iqbal et al Mild to moderate 
anaemia common 
Mild to moderate 
anaemia common 
WBC count Iqbal et al Leucocytosis 
common 
Severe leucopenia 
common 
Platelet count Iqbal,et al Mild to moderate 
thrombocytopenia 
common 
Mild to moderate 
thrombocytopenia  
common 
Splenomegaly Laurence et al 65% 53% 
Hyperferritinemia Melissa et al 70-90% 87% 
Hypertriglyceridiemia Chandra et al 45% 59% 
Hypofibrinogenemia Chandra et al 
Melissa et al 
40% 31% 
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Entity compared 
Authors of the 
study 
Conclusion 
Conclusion from 
this study 
CD 68 for 
trephine 
Caleb Ho et al  Increased 
sensitivity &  
enabled 
quantification 
Did not increase 
sensitivity 
Primary HLH Ling et al 25% 3% 
Most common 
cause for 
secondary HLH 
Melissa et al & 
Chandra et al 
Infections Infections 
Infection 
associated HLH 
Ling et al 
Chandra et al 
Melissa et al 
Bacterial > others 
Bacteria=viral 
Viral> others 
Bacterial > others 
TB associated 
HLH 
Tseng et al 25% 23% 
Common viral 
associated HLH 
Ramachandran et al 
Ling et al 
Dengue ( 12%) 
EBV(18%) 
HIV 
&Dengue(9%) 
Malignancy 
associated HLH 
Ling et al, Melissa 
et al, Michael et al 
Second most 
common HLH 
Second most 
common HLH 
Common 
Lymphoma with 
associated HLH 
Parikh et 
al,Lehemberg et al 
& Shabbir et al 
 
Otrock & Eby et al 
T cell lymphoma 
 
 
 
B cell lymphoma 
B cell lymphoma 
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Entity compared Authors of the 
study 
Conclusion  Conclusion from 
this study 
HLH in Aplastic 
anaemia 
Elena et al 3% 3% 
HLH in SLE  Cesar et al 15% 3% 
Kikuchi with 
HLH 
Nishiwaki et al Rare presentation 3% of cases 
HLH with poor 
prognosis 
Michael et al Malignancy 
associated HLH 
Malignancy 
associated HLH 
 
LIMITATIONS OF THIS STUDY 
 The techniques for measuring NK cell activity and CD 25 levels were 
not available in our institution so those parameters were not analysed in 
our study 
 The facilities for molecular diagnosis of mutations associated with 
primary haemophagocytic lymphohistiocytosis were also not available 
which was probably responsible for the decreased incidence of primary 
HLH (3%) in our study when compared to other studies. 
 Information regarding therapeutic response and prognosis of the patients 
were not available to us as many patients were lost to follow up. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary and Conclusion  
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SUMMARY & CONCLUSION 
 The mean age of presentation of HLH is 30.7 years 
 Prolonged and persistent fever is the most common presentation of 
patients with HLH 
 Mild to moderate anaemia, severe leucopenia and mild to moderate 
thrombocytopenia are common 
 Ferritin levels of > 2000ng/ml are more diagnostic of HLH than any other 
parameter. In our study almost 100 % of cases with ferritin levels of  > 
2000ng/ml were specific for HLH. 
 CD 68 can be used to highlight haemophagocytosis in trephine biopsy. 
However in our study it did not help to increase the sensitivity of 
detection. 
 The incidence of primary HLH is only 3% which can be an underestimate 
due to our limited facilities for molecular diagnosis. 
 The most common cause for secondary HLH is infections followed by 
malignancies. 
 Tuberculosis is the most common bacterial infection while Dengue is the 
most common viral infection associated HLH 
 Lymphoma is the most common malignancy associated HLH. 
 We had rare cases of Kikuchi Fujimoto disease & Diffuse large B cell 
lymphoma presenting as HLH. 
 Prognosis of malignancy associated HLH was bad. 
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Thus, HLH is a diverse disorder which can present with varied clinical 
manifestations. There are many factors which contribute to the 
aetiopathogenesis of HLH. Because of the complex pathway of pathogenesis 
and different clinical presentations many of the HLH cases go under 
recognised. This remains the main cause for increased morbidity and mortality 
in persons with HLH.  
In our study we have made conclusions regarding the clinical 
manifestations and aetiologies of HLH which will aid in the early diagnosis. 
Hereby we recommend that all patients with the clinical suspicion of HLH have 
to be carefully evaluated for the possible aetiology. A thorough and careful 
screening of bone marrow of these patients suspected to have HLH is essential 
for early diagnosis and prompt treatment. In spite of emergence of many 
treatment regimens for HLH, haematopietic stem cell transplantation remains 
the final option for treatment of patients with HLH. Hence more studies are 
required to raise awareness of this syndrome and improve the effectiveness of 
the existing treatment regimen. 
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1 21 MALE YES YES NO YES - - SCRUB TYPHUS 
2 10 FEMALE YES NO YES YES YES NO KIKUCHI FUJIMOTO 
3 50 MALE YES YES YES - - YES NON HODGKINS LYMPHOMA 
4 39 MALE YES NO NO YES YES - TUBERCULOSIS 
5 20 MALE YES YES YES YES NO YES SEPSIS 
6 8 FEMALE YES YES YES YES YES - SEPSIS 
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11 36 FEMALE YES NO YES NO YES - TUBERCULOSI- ABDOMEN 
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13 15 DAYS MALE YES NO NO YES NO NO PRIMARY HLH 
14 34 DAYS MALE YES YES YES YES YES YES PNEUMONIA 
15 60 MALE YES NO YES YES - - SEPSIS 
16 16 FEMALE YES YES NO YES YES YES TYPHOID 
17 51 MALE YES YES YES YES YES - DENGUE 
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